CompaniesGalimedix Therapeutics
Galimedix Therapeutics logo

Galimedix Therapeutics

active
Berlin, Germany
Website
About

Small Molecules for Neurodegenerative, Ophthalmology

Areas of Focus

Categories

Small Molecule Pharmaceutical
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

110

By Phase

PHASE2: 1

By Status

RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
2028
Today
NCT06659549
Hover over trial bars to see details

Recent Trials

NCT06659549Lead Sponsor
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
PHASE2Recruiting
110 participants
Started: Jan 10, 2025 · Completed: May 30, 2027
Locations (1)
Headquarters
Berlin, Germany
Map

Loading map...